Incyte (INCY) vs Krystal Biotech (KRYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Krystal Biotech (KRYS) has outperformed Incyte (INCY) over the past year, gaining 74.9% versus a gain of 32.1%. Over five years, KRYS leads with a +571.8% price change compared with +72.0% for INCY. Incyte is the larger company by market cap ($22.85 billion vs $9.69 billion), about 2.4 times the size, while Krystal Biotech is growing revenue faster (+33.9% vs +21.2%).
On valuation, Incyte trades at a lower forward P/E (12.9x vs 35.3x for Krystal Biotech). Krystal Biotech converts more of its revenue into profit, with a net margin of 52.6% versus 25.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCY | KRYS |
|---|---|---|
| Share price | $112.75 | $327.30 |
| Market cap | $22.85B | $9.69B |
| 1-day change | -0.61% | +0.84% |
| YTD return | +14.15% | +32.76% |
| 1-year return | +32.06% | +74.86% |
| 5-year return | +71.98% | +571.80% |
| P/E ratio (TTM) | 14.36 | 41.02 |
| Forward P/E | 12.89 | 35.33 |
| EPS (TTM) | $7.85 | $7.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.14B | $389.13M |
| Revenue growth (YoY) | +21.22% | +33.94% |
| Net income (latest FY) | $1.29B | $204.83M |
| Gross margin | 92.76% | — |
| Operating margin | 29.46% | 41.45% |
| Net margin | 25.03% | 52.64% |
| 52-week high | $132.60 | $382.54 |
| 52-week low | $82.82 | $179.19 |
| Distance from 52-week high | -14.97% | -14.44% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +14.53% | +19.80% |
| Average volume | 1.63M | 381.18K |
| Shares outstanding | 202.70M | 29.60M |
| Employees | 2,844 | 295 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Incyte is about 2.4 times larger than Krystal Biotech by market value ($22.85B vs $9.69B).
- KRYS has outperformed INCY by 42.8 percentage points over the past year.
- Krystal Biotech trades at a higher earnings multiple (41.0x vs 14.4x trailing P/E).
- Krystal Biotech is more profitable, keeping 52.6 cents of every revenue dollar as net income versus 25.0 cents for Incyte.
- Krystal Biotech grew revenue faster in its latest fiscal year (+33.94% vs +21.22%).
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 2,844 employees
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
INCY vs KRYS FAQ
Which is bigger, Incyte or Krystal Biotech?
Incyte (INCY) is larger, with a market capitalization of $22.85B compared with $9.69B for Krystal Biotech (KRYS).
Which stock has performed better over the past year, INCY or KRYS?
KRYS returned +74.86% over the past 12 months, compared with +32.06% for INCY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, INCY or KRYS?
INCY has the lower trailing P/E at 14.4, versus 41.0 for KRYS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Incyte and Krystal Biotech in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for Incyte and Biotechnology: Biological Products (No Diagnostic Substances) for Krystal Biotech.